Hong Kong Pharmaceuticals & Biotech Growth at Reasonable Price

Cutia Therapeutics

Market Cap: HK$2.1b

An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.

Innovent Biologics

Market Cap: HK$84.1b

A biopharmaceutical company, develops, manufactures and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in China.